The use of surrogate end points as a basis for reaching conclusions
about the benefit of therapy has been met with both rising enthusiasm, reflected
in recent changes in the Food, Drug and Cosmetic Act1
and some recent US Food and Drug Administration (FDA) actions, and rising
concern, reflected in several strongly stated warnings.2- 4
The mixed response is not surprising: reliance on surrogates, when the surrogate
proves to predict clinical benefit, can bring treatment benefits to patients
years before information on clinical outcomes could be available and at relatively
low cost. But reliance on surrogates, when the effect on the surrogate does
not lead to clinical benefit, can lead to the adoption of useless or even
harmful therapies. The obvious community goal is to make decisions most likely
to yield the former of these outcomes.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 145
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination EDUCATION GUIDESClubbing
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.